4 Stocks Underperforming Today In The Health Services Industry

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 62 points (-0.4%) at 15,060 as of Wednesday, June 12, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 760 issues advancing vs. 2,254 declining with 88 unchanged.

The Health Services industry currently sits down 0.10 versus the S&P 500, which is down 0.61. On the negative front, top decliners within the industry include Agilent Technologies ( A), down 0.95, Thermo Fisher Scientific ( TMO), down 0.95 and Catamaran ( CTRX), down 0.70. A company within the industry that increased today was Smith & Nephew ( SNN), up 2.27.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today:

4. Ironwood Pharmaceuticals ( IRWD) is one of the companies pushing the Health Services industry lower today. As of noon trading, Ironwood Pharmaceuticals is down $0.57 (-4.5%) to $12.24 on average volume Thus far, 513,858 shares of Ironwood Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $12.16-$13.00 after having opened the day at $12.82 as compared to the previous trading day's close of $12.81.

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. Ironwood Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector. Shares are up 19.2% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Ironwood Pharmaceuticals a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Ironwood Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Ironwood Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, HCA Holdings ( HCA) is down $0.30 (-0.8%) to $39.43 on average volume Thus far, 1.4 million shares of HCA Holdings exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $39.34-$40.29 after having opened the day at $40.24 as compared to the previous trading day's close of $39.73.

HCA Holdings, Inc., through its subsidiaries, provides health care services in the United States. HCA Holdings has a market cap of $18.0 billion and is part of the health care sector. The company has a P/E ratio of 13.2, below the S&P 500 P/E ratio of 17.7. Shares are up 31.7% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates HCA Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, poor profit margins and weak operating cash flow. Get the full HCA Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Intuitive Surgical ( ISRG) is down $4.73 (-0.9%) to $494.84 on light volume Thus far, 73,473 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 407,900 shares. The stock has ranged in price between $494.12-$503.53 after having opened the day at $501.18 as compared to the previous trading day's close of $499.57.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $20.5 billion and is part of the health care sector. The company has a P/E ratio of 29.9, above the S&P 500 P/E ratio of 17.7. Shares are up 4.0% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Intuitive Surgical a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Intuitive Surgical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Medtronic ( MDT) is down $0.33 (-0.6%) to $51.74 on average volume Thus far, 2.5 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.6 million shares. The stock has ranged in price between $51.73-$52.48 after having opened the day at $52.26 as compared to the previous trading day's close of $52.07.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $52.7 billion and is part of the health care sector. The company has a P/E ratio of 15.4, below the S&P 500 P/E ratio of 17.7. Shares are up 26.9% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Medtronic a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Medtronic Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Synergy Pharmaceuticals Secures Approval for Linzess Competitor